Mirum Pharma Exceeds 2025 Sales Guidance, Projects Strong 2026 Growth, and Boosts Pipeline with HDV Acquisition

summarizeSummary

Mirum Pharmaceuticals announced preliminary 2025 net product sales exceeding guidance, issued strong 2026 revenue projections, and revealed a strategic acquisition of Bluejay Therapeutics to add a late-stage HDV asset, all while accelerating key pipeline timelines.

check_boxKey Events

• Strong 2025 Sales Performance

  Mirum Pharmaceuticals reported preliminary unaudited net product sales of approximately $520 million for fiscal year 2025, exceeding the upper end of its previous guidance.

• Robust 2026 Revenue Guidance

  The company provided 2026 global net product sales guidance of $630 million to $650 million, signaling substantial continued growth.

• Strategic Acquisition of Bluejay Therapeutics

  Mirum announced the proposed acquisition of Bluejay Therapeutics, adding worldwide rights to brelovitug, a late-stage monoclonal antibody for chronic hepatitis delta virus (HDV) with FDA Breakthrough and EMA PRIME designations. This acquisition is expected to close in mid-to-late January 2026 and is supported by approximately $268.5 million in private placements.

• Accelerated Pipeline Development

  The timing for the LIVMARLI EXPAND Phase 3 study in additional cholestatic pruritus settings has been accelerated, with topline data now expected in Q4 2026. Multiple other clinical catalysts are also anticipated in 2026.

auto_awesomeAnalysis

Mirum Pharmaceuticals reported preliminary 2025 net product sales of approximately $520 million, surpassing the upper end of its guidance, demonstrating robust commercial execution. The company also provided strong 2026 global net product sales guidance of $630 million to $650 million, indicating significant continued growth. Furthermore, the proposed acquisition of Bluejay Therapeutics, expected to close in January 2026, strategically expands Mirum's late-stage pipeline with brelovitug for chronic hepatitis delta virus (HDV), an asset with FDA Breakthrough and EMA PRIME designations. This move, supported by $268.5 million in private placements, enhances future revenue potential. The acceleration of the LIVMARLI EXPAND study timeline, with topline data now expected in Q4 2026, further underscores pipeline momentum. These combined factors, announced while the stock is trading near its 52-week high, significantly strengthen the company's investment thesis by highlighting strong financial performance, strategic growth, and an expanding, de-risked pipeline.